Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor (Nasdaq: DXR) launched a BVA diagnostic program in Southern Middle Tennessee, expanding its outpatient cardiology presence on Feb. 24, 2026.

Rhea-AI Summary

Daxor (Nasdaq: DXR) launched a BVA diagnostic program in Southern Middle Tennessee, expanding its outpatient cardiology presence on Feb. 24, 2026. The program uses the Tennessee-based ezBVA Lab to deliver comprehensive blood volume metrics with a 24-hour turnaround and claims 98% accuracy.

According to the company, the service integrates into outpatient workflows with existing reimbursement codes and requires zero capital investment for the facility.

Positive

• Regional expansion into Southern Middle Tennessee outpatient market
• 98% diagnostic accuracy for blood volume measurements
• 24-hour turnaround on comprehensive blood volume metrics
• No capital investment required for participating facilities
• Reimbursement codes available for outpatient BVA testing

Negative

• None.

Argus Feb 24 session

-1.72% close to close Open Argus

Details

News Market Reaction – DXR

In the Feb 24 session, DXR declined 1.72%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands DXR’s BVA footprint into a high-volume outpatient cardiology setting in So...

Analysis

This announcement expands DXR’s BVA footprint into a high-volume outpatient cardiology setting in Southern Middle Tennessee, leveraging its ezBVA Lab for 24-hour blood volume metrics with cited 98% accuracy. It builds on prior facility adoptions and the company’s shift toward an operating diagnostics model. Investors may track future disclosures for utilization levels at this site, additional outpatient contracts, and how these deployments impact revenue trends and operating leverage over time.

Key Figures

Diagnostic accuracy: 98% Turnaround time: 24 hours

Diagnostic accuracy

98%

Accuracy rate for Daxor’s BVA diagnostics cited in Tennessee program launch

Turnaround time

24 hours

ezBVA Lab blood volume metrics turnaround for the Tennessee facility

Historical Context

5 past events · Latest: Feb 10

5 events

1. Feb 10

   Reporting transition

   24h Move

   -0.4%

   Shift to Exchange Act reporting and focus on diagnostics business.

2. Jan 23

   Capital raise

   24h Move

   -8.1%

   Registered direct offering of common stock for gross proceeds of $9M.

3. Nov 25

   Facility expansion

   24h Move

   -1.9%

   Three new facility adoptions and deployment of next-gen BVA analyzer.

4. Oct 21

   Investor meetings

   24h Move

   +2.0%

   CEO participation in Maxim Growth Summit with institutional investor meetings.

5. Oct 15

   Product showcase

   24h Move

   -1.0%

   Showcasing new BVA technology at MedAxiom cardiovascular conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

diagnostic, reimbursement codes

2 terms

diagnostic medical

"our gold-standard diagnostic into the outpatient setting"

Diagnostic describes a medical test, tool, device, or process used to detect, identify, or measure a disease, condition, or biological marker. For investors, diagnostics matter because they determine how many tests are sold, how quickly results change patient care, and what regulatory approval or reimbursement is required — similar to how a better smoke alarm can increase safety and demand, improvements in diagnostics can expand market size and influence a company’s revenue and competitive position.

reimbursement codes financial

"outpatient setting, which has reimbursement codes with no capital investment"

Reimbursement codes are standardized identifiers used by insurance companies and government programs to classify medical services, procedures and drugs so providers can bill for payment. Think of them like barcodes or price tags that determine what a treatment is called and how much insurers will pay; getting the right code affects whether a product is paid for, how quickly it is adopted, and how much revenue a healthcare company can expect.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment 

Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management.

Utilizing Daxor’s proprietary, Tennessee-based ezBVA Lab workflow, the facility will benefit from a 24-hour turnaround time on comprehensive blood volume metrics, enabling rapid, data-driven clinical decisions for cardiology patients throughout the region.

“This milestone marks another significant step in our regional expansion and underscores the critical role of precise volume assessment in patient care," said Michael Feldschuh, Daxor CEO and President. "With 98% accuracy, our technology empowers clinicians to move beyond 'best guesses' to data-driven fluid management. By utilizing our ezBVA Lab service, clinicians can implement our gold-standard diagnostic into the outpatient setting, which has reimbursement codes with no capital investment. This can meaningfully contribute significantly to improving patient outcomes and reducing healthcare costs.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Daxor (DXR) announce on February 24, 2026 about a Tennessee BVA program?

Daxor launched a BVA diagnostic program at a high-volume outpatient facility in Southern Middle Tennessee on Feb. 24, 2026. According to the company, the program uses the Tennessee-based ezBVA Lab for 24-hour results and claims 98% diagnostic accuracy with existing reimbursement codes.

How accurate and fast is Daxor's ezBVA Lab testing for DXR patients in Tennessee?

The ezBVA Lab testing is reported to deliver 98% accuracy with a 24-hour turnaround on comprehensive blood volume metrics. According to the company, this enables more rapid, data-driven fluid management decisions in outpatient cardiology settings.

Does the new DXR outpatient program require capital investment from the Tennessee facility?

No, the program requires zero capital investment from the participating facility, per the company. According to the company, clinicians can integrate the ezBVA Lab service using existing reimbursement codes without upfront equipment spending.

What clinical benefit does Daxor (DXR) claim for outpatient cardiology patients in Tennessee?

Daxor says the program enables clinicians to use precise blood volume metrics to improve fluid management and clinical decisions. According to the company, that accuracy and speed may support better chronic disease management and potentially reduced healthcare costs.

How will clinicians in Tennessee access Daxor's BVA diagnostics through DXR's ezBVA Lab?

Clinicians will utilize Daxor's Tennessee-based ezBVA Lab workflow to order tests and receive results within 24 hours. According to the company, the service integrates into outpatient workflows and uses reimbursement codes, enabling adoption without facility capital outlay.